Skip to the main content.

KBI Biopharma

3 min read

Oragenics Engages KBI Biopharma to Support Development of the Intranasal COVID-19 Vaccine Candidate NT-CoV2-1

KBI TO PRODUCE MATERIAL FOR USE IN FUTURE EXPECTED PHASE 2 CLINICAL TRIAL OF ORAGENICS’ INTRANASAL VACCINE CANDIDATE

Read More